Pericoital Oral Contraception With Levonorgestrel

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
FHI 360
ClinicalTrials.gov Identifier:
NCT00922233
First received: June 10, 2009
Last updated: August 22, 2013
Last verified: August 2013
  Purpose

A prospective, open-label, single arm, multicenter study to evaluate efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel


Condition Intervention Phase
Healthy
Drug: levonorgestrel
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Pericoital Oral Contraception With Levonorgestrel: A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Acceptability

Resource links provided by NLM:


Further study details as provided by FHI 360:

Primary Outcome Measures:
  • Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35) [ Time Frame: 6.5 months ] [ Designated as safety issue: No ]
    Participants were followed for 6.5 months.Pearl Index in the 18-35 year population was collected excluding months in which barrier methods, condoms, or emergency contraception were used unless the subject conceived

  • Participant Report of Adverse Events. [ Time Frame: 6.5 months ] [ Designated as safety issue: Yes ]
    Safety data includes data from each subject up to two weeks after her last use of the study tablets as well as all events deemed related to study product, regardless of date last tablet was taken


Secondary Outcome Measures:
  • Acceptability Based on Bleeding Patterns Reported [ Time Frame: 6.5 months ] [ Designated as safety issue: No ]
    Number of participants who reported bleeding patterns were acceptable and would therefore use Levonorgestrel


Enrollment: 72
Study Start Date: January 2010
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Levonorgestrel
0.75 mg of levonorgestrel within 24 hours of sex
Drug: levonorgestrel
oral contraceptive pills

Detailed Description:

This is a prospective, open-label, single arm, multicenter study to evaluate efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel (LNG). The objectives of the study as stated in the study protocol are as follows:

  • To evaluate the efficacy of the study regimen among women who have sex 1-4 days a month and who are relying on the study regimen as their primary method of contraception
  • To evaluate the safety of this regimen, with particular emphasis on its effects on vaginal bleeding patterns and anemia
  • To evaluate the acceptability of the regimen The study will enroll fertile women of reproductive age who have sex up to 6 days a month, are at low risk for sexually transmitted infections (STIs), have no contraindications to progestin-only oral contraceptives,have no serious contraindications to pregnancy, and are willing to use an investigational method of contraception as their only contraceptive method for 6.5 months (each tablet contains 0.75 mg LNG to be used after every sex act).
  Eligibility

Ages Eligible for Study:   up to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Each woman enrolled in the trial must meet the following inclusion criteria:

  • Competent to provide informed consent to participate in the trial and has done so.
  • At least the minimum age is 18 to 45 years old.
  • Had sex 1 to 4 days in past month and expects to continue at that frequency for the next 6.5 months.
  • At low risk for sexually transmitted infection (STI), operationally meaning that neither she nor her partner to her knowledge has had any of the following:

    • More than one sexual partner currently or any expectation of having more than one sexual partner in the next 6.5 months
    • Diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
    • Treatment for a STI within the past 6 months, excluding recurrent genital herpes or condyloma
    • Sharing of illicit injection drug equipment ever in the past.
  • Willing to use the study regimen as her only contraceptive method for the next 6.5 months (except that she may also use condoms if needed for protection from STIs).
  • Wants to avoid pregnancy for at least the next 6.5 months.
  • Willing to accept an uncertain risk of pregnancy during the study.
  • Gives correct answers to the informed consent quiz.
  • Willing and able to follow all study requirements.

Exclusion Criteria:

To be eligible for enrollment, a woman must not meet any of the following exclusion criteria:

  • Pregnant as verified by a pregnancy test at enrollment.
  • Has an indication of current subfecundity, specifically:

    • Her last pregnancy ended within the last 8 weeks, or she has had fewer than two menstrual periods since resolution of last pregnancy
    • She has not had normal monthly menses for the past 2 months
    • She is currently breastfeeding
    • She has used any hormonal contraceptive other than emergency contraceptive pills since the onset of her last menstrual period
    • Has received an injection of a long term injectable contraceptive in the last 9 months
    • Currently has an intrauterine device
    • Has had a sterilization procedure or ectopic pregnancy
    • Has been diagnosed by a clinician as having a fertility problem
    • Her partner has had a sterilization procedure or infertility diagnosis, to her knowledge.
  • She currently has known contraindications to progestin-only pills, specifically including the following conditions:

    • Unexplained abnormal vaginal bleeding
    • Deep venous thrombosis or pulmonary embolus
    • Active viral hepatitis
    • Decompensated cirrhosis
    • Liver tumor
    • History of breast cancer within the past 5 years.
  • Has a breast mass on examination.
  • Has a personal or family history suggestive of predisposition to thrombosis.
  • Has a serious contraindication to pregnancy (medical condition or use of chronic medication such as isotretinoin or thalidomide).
  • Taking drugs that are known to interact with progestins (such as rifampicin or anticonvulsant medications).
  • Has previously participated in this study.
  • Currently participating in another medical research study.
  • The site investigator or designee perceives another reason to exclude her from the trial.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00922233

Locations
United States, Colorado
Planned Parenthood of the Rocky Mountains
Denver, Colorado, United States, 80232
United States, Texas
Planned Parenthood Gulf Coast, Inc.
Houston, Texas, United States, 77004
United States, Utah
Planned Parenthood Association of Utah
Salt Lake City, Utah, United States, 84102
Brazil
CEMICAMP
Campinas, Brazil
Sponsors and Collaborators
FHI 360
Investigators
Principal Investigator: Vera Halpern, MD FHI 360
  More Information

No publications provided

Responsible Party: FHI 360
ClinicalTrials.gov Identifier: NCT00922233     History of Changes
Other Study ID Numbers: 10139
Study First Received: June 10, 2009
Results First Received: May 24, 2013
Last Updated: August 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by FHI 360:
Contraception

Additional relevant MeSH terms:
Levonorgestrel
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Contraceptives, Oral, Synthetic
Contraceptives, Oral

ClinicalTrials.gov processed this record on April 17, 2014